Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more
Kwangdong Phar (009290) - Total Liabilities
Latest total liabilities as of September 2025: ₩589.90 Billion KRW
Based on the latest financial reports, Kwangdong Phar (009290) has total liabilities worth ₩589.90 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kwangdong Phar - Total Liabilities Trend (2011–2024)
This chart illustrates how Kwangdong Phar's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kwangdong Phar Competitors by Total Liabilities
The table below lists competitors of Kwangdong Phar ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
North East Rubbers Public Company Limited
BK:NER
|
Thailand | ฿10.73 Billion |
|
Atria Oyj A
HE:ATRAV
|
Finland | €544.60 Million |
|
GD Culture Group Limited
NASDAQ:GDC
|
USA | $3.84 Million |
|
Provident Bancorp Inc
NASDAQ:PVBC
|
USA | $1.25 Billion |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥420.46 Million |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
USA | $5.42 Million |
|
Cloud Live Technology Group Co Ltd
SHE:002306
|
China | CN¥691.61 Million |
|
Prabha Energy Limited
NSE:PRABHA
|
India | ₹2.21 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Kwangdong Phar's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kwangdong Phar's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kwangdong Phar (2011–2024)
The table below shows the annual total liabilities of Kwangdong Phar from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩552.01 Billion | +12.65% |
| 2023-12-31 | ₩490.02 Billion | +27.28% |
| 2022-12-31 | ₩384.98 Billion | +7.96% |
| 2021-12-31 | ₩356.60 Billion | +8.57% |
| 2020-12-31 | ₩328.46 Billion | -4.88% |
| 2019-12-31 | ₩345.32 Billion | +14.64% |
| 2018-12-31 | ₩301.22 Billion | -1.69% |
| 2017-12-31 | ₩306.40 Billion | +9.39% |
| 2016-12-31 | ₩280.10 Billion | -2.08% |
| 2015-12-31 | ₩286.06 Billion | +123.25% |
| 2014-12-31 | ₩128.13 Billion | -4.98% |
| 2013-12-31 | ₩134.85 Billion | +10.39% |
| 2012-12-31 | ₩122.16 Billion | +69.28% |
| 2011-12-31 | ₩72.16 Billion | -- |